Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary
Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary
复制标题
DOI：
10.1136/jcp.2010.080234
复制
发表时间：
2010-10
影响因子：
3.4
通讯作者：
T. Umezu;K. Shibata;H. Kajiyama;E. Yamamoto;A. Nawa;F. Kikkawa
中科院分区：
文献类型：
--
作者：
T. Umezu;K. Shibata;H. Kajiyama;E. Yamamoto;A. Nawa;F. Kikkawa
背景磷脂酰肌醇蛋白聚糖3（GPC 3）是一种膜结合硫酸乙酰肝素蛋白聚糖，可能在促进癌细胞生长和分化中发挥作用。最近的研究报道，GPC 3在卵巢透明细胞癌（CCC）中过表达，而不是其他卵巢组织型。然而，在CCC患者中，GPC 3过表达与预后之间的关系尚未阐明。目的应用免疫组织化学方法检测胆囊癌组织中GPC 3的表达。方法与结果在52例CCC患者中，GPC 3阳性表达率为40.4%。在CCC的情况下，GPC 3的表达和临床病理因素，如年龄，FIGO分期，CA 125值，腹膜细胞学，腹水量和死亡率之间没有相关性，除了残留肿瘤的大小。GPC 3表达与I期CCC患者的无进展生存率相关。GPC 3阳性区Ki-67阳性细胞数低于GPC 3阴性区。GPC 3的表达可能与CCC细胞的低增殖率有关。在CCC的早期阶段，GPC 3表达的患者倾向于对基于紫杉烷的治疗耐药。结论GPC 3的过度表达可能与卵巢癌的低水平增殖有关，可能与卵巢癌对紫杉烷类化疗药物的耐药及预后不良有关。
Background Glypican-3 (GPC3), a membrane-bound heparan sulphate proteoglycan, may play a role in promoting cancer cell growth and differentiation. Recent studies reported that GPC3 is overexpressed in clear cell carcinoma (CCC) of the ovary, and not other ovarian histotypes. However, in CCC patients, the relationship between the overexpression of GPC3 and prognosis has not yet been clarified. Aim To evaluate GPC3 expression by immunohistochemistry in CCC. Methods and Results In 52 CCC patients, GPC3 expression was observed in 40.4%. In cases of CCC, no correlations were identified between GPC3 expression and clinicopathological factors, such as age, FIGO stage, CA125 values, peritoneal cytology, ascitic fluid volume and mortality rate, except for the residual tumour size. GPC3 expression was associated with poor progression-free survival in stage I CCC patients. The numbers of Ki-67-stained cells in GPC3-positive areas were lower than those in GPC3-negative areas. GPC3 expression may be associated with a low proliferation rate in CCC cells. In the early stage of CCC, GPC3-expressing patients tended to be resistant to taxane-based treatment. Conclusions Results suggest that the overexpression of GPC3 may be related to the low-level proliferation of tumours; it may be associated with resistance to taxane-based chemotherapy and a poor prognosis in CCC of the ovary.